Clinical trials: Normal Population
Systemic Lupus Erythematosus
Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)
The primary objective of the study is to evaluate the safety, tolerability and Pharmacokinetics (PK) of Epratuzumab in Japanese subjects with moderate to severe general SLE as add on to standard of care treatment during the trial.
- Trial name
- NCT01449071
- Testing
- Epratuzumab 400 mg, Epratuzumab 1200 mg, Epratuzumab 100 mg
- Where
- 7 sites in Japan
- Volunteers
- 20 people
- Sponsor
- UCB Pharma
Diabetic Foot Ulcer of Neuropathic Origin
The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Southern Europe The TRANS-South Study
Trafermin is a recombinant human basic fibroblast growth factor (bFGF; original development code, KCB-1), which is manufactured by genetic engineering using Escherichia coli by Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan).
- Trial name
- TRANS-South (NCT01217463)
- Testing
- Trafermin 0.01% spray
- Where
- 24 sites in Czechia, France and 2 more
- Volunteers
- 201 people
- Sponsor
- Olympus Biotech Corporation
Actinic Keratoses
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
The purpose of this study is to determine whether topical application of PEP005 is effective for the treatment of actinic keratoses.
- Trial name
- NCT00942604
- Testing
- PEP005 (ingenol mebutate) Gel, Vehicle gel
- Where
- 17 sites in United States
- Volunteers
- 203 people
- Sponsor
- Peplin
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Diabetes, Foot Ulcer
Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer
It is estimated that 300 million people worldwide will have diabetes by the year 2025. About 12 percent of those with diabetes will have had a foot ulcer, which is a major source of morbidity, concern, and cost.
- Trial name
- DERMAGEN® (NCT00521937)
- Testing
- Dermagen®
- Where
- 7 sites in France
- Volunteers
- 388 people
- Sponsor
- Laboratoires Genévrier
Diabetic Foot Ulcers
Phase IV Study to Evaluate the Efficacy of AMNIOEXCEL in Diabetic Foot Ulcers
The primary goal of the study is to demonstrate the increased rate of complete wound closure by AMNIOEXCEL® compared to routine care in patients with chronic diabetic foot ulcers
- Trial name
- NCT02209051
- Testing
- AMNIOEXCEL, Standard of Care, Diabetic Foot Ulcers
- Where
- 8 sites in United States
- Volunteers
- 29 people
- Sponsor
- Integra LifeSciences Corporation
Neutropenic Complications, Breast Neoplasms
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®
The study will assess the efficacy of LA-EP2006 compared to Neulasta® with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
- Conditions
- Neutropenic Complications, Breast Neoplasms, Chemotherapy-induced Neutropenia, Chemotherapeutic Toxicity
- Trial name
- PROTECT-1 (NCT01735175)
- Testing
- LA-EP2006, Neulasta®
- Where
- 41 sites in Brazil, India and 4 more
- Volunteers
- 316 people
- Sponsor
- Sandoz
Healthy Volunteer Study, Hepatic Impairment
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose
- Conditions
- Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
- Trial name
- NCT06911320
- Testing
- Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Behçet's Syndrome
A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease
The main objective of this study is to evaluate the efficacy and safety of apremilast in the treatment of oral ulcers in adults with active Behçet's disease (BD).
- Trial name
- NCT02307513
- Testing
- Apremilast
- Where
- 63 sites in United States, France and 8 more
- Volunteers
- 207 people
- Sponsor
- Amgen
Postherpetic Neuralgia, Neuralgia
An Effectiveness and Safety Study With RWJ-333369 (Carisbamate) for the Study of Postherpetic Neuralgia (PHN).
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of 200 mg of RWJ-333369 given twice daily compared with placebo in the treatment of postherpetic neuralgia.
- Conditions
- Postherpetic Neuralgia, Neuralgia, Herpes Zoster
- Trial name
- NCT00492323
- Testing
- carisbamate
- Volunteers
- 91 people
- Sponsor
- SK Life Science, Inc.
Inflammatory Rosacea
Study of 0444 Gel in the Treatment of Inflammatory Lesions of Rosacea
The aim of this trial is to assess the efficacy of Metronidazole Topical Gel 1% in the Treatment of Inflammatory Lesions of Rosacea.
- Trial name
- NCT01016782
- Testing
- 0444
- Volunteers
- 867 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Rheumatoid Arthritis
A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes
The main objective of this study is to compare the pharmacokinetics (PK) of the abatacept drug product converted from drug substance by a new drug substance process (Treatment A) relative to the current drug substance process…
- Trial name
- NCT03714022
- Testing
- Abatacept
- Where
- 2 sites in United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Diabetic Foot Ulcers
Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers
The purpose of the study is to determine if DSC127 is effective in increasing incidence of complete wound closure at 10 weeks confirmed at a visit 2 weeks later when compared to the vehicle (gel without active ingredient) in…
- Trial name
- STRIDE 1 (NCT01830348)
- Testing
- DSC127
- Where
- 25 sites in United States
- Volunteers
- 266 people
- Sponsor
- Integra LifeSciences Corporation
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after…
- Trial name
- CAPACITY (NCT04084678)
- Testing
- Ralinepag
- Where
- 33 sites in United States, Argentina and 10 more
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Giant Cell Arteritis (GCA)
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
- Trial name
- GCAptAIN (NCT04930094)
- Testing
- Secukinumab 300 mg, Secukinumab 150 mg
- Where
- 104 sites in United States, Argentina and 25 more
- Volunteers
- 354 people
- Sponsor
- Novartis Pharmaceuticals
Acne Vulgaris
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris
- Trial name
- NCT03003247
- Testing
- IDP-120 Gel, IDP 120 Component A Gel, IDP 120 Component B Gel
- Where
- 24 sites in United States, Canada
- Volunteers
- 364 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Dermatitis, Atopic
A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis
The purpose of this study is to assess the safety and effectiveness of 2 doses of ustekinumab compared with placebo (inactive medication) in adult Japanese participants with severe atopic dermatitis.
- Trial name
- NCT01945086
- Testing
- Ustekinumab, Concomitant topical medications for atopic dermatitis
- Where
- 13 sites in Japan
- Volunteers
- 79 people
- Sponsor
- Janssen Pharmaceutical K.K.
Lupus Nephritis
A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.
This 2 arm study assessed the efficacy of Mycophenolate Mofetil (MMF; CellCept) compared to cyclophosphamide in inducing a response in patients with lupus nephritis, and the long term efficacy of MMF compared to azathioprine in…
- Trial name
- NCT00377637
- Testing
- Mycophenolate mofetil (MMF), Cyclophosphamide, Azathioprine
- Where
- 108 sites in United States, Argentina and 15 more
- Volunteers
- 370 people
- Sponsor
- Hoffmann-La Roche
Dermatitis, Atopic
Atopic Dermatitis in Atopy Predisposed Infants
The primary objective of this study is to investigate the effectiveness of a standardized skin care regimen using a milk lotion once daily and a bathing addendum as needed during the first 52 weeks of life on the development of…
- Trial name
- ADAPI (NCT02906475)
- Testing
- standardized skin care regimen
- Where
- Germany
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- HiPP GmbH & Co. Vertrieb KG
Healthy
To Test the Effect of Selected Fibres and Flours in Flat Bread on Post-Prandial Blood Glucose and Insulin Responses in Healthy Indian Population
Double-blind, randomized, controlled, cross-over design with 3 test products and one control product. To evaluate the effect of 4 different flour compositions (guar gum 2% and 4%, chickpea flour 15% and barley flour 2% and 5%) of…
- Trial name
- NCT02814357
- Testing
- Control (market standard), wheat flour, chickpea flour
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.